CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
CHA Biotech Co., Ltd., a biotech firm developing and manufacturing cell therapy-related optical, digital, and medical products, has partnered with CanCure, a US-based immunotherapy biotech firm. They agreed to co-develop natural killer (NK) cell therapy.
CHA Biotech confirmed its collaboration with CanCure on Monday, Jan. 29. According to The Korea Times, the company signed a material transfer agreement to design and produce an anti-MIC antibody treatment.
The NK Cells Therapy
It was explained that the anti-MIC antibody earmarks the MIC antigen (MHC class I polypeptide-related sequence) demonstrated by cancer cells. Moreover, the MIC alludes to a type of protein that plays a crucial part in regulating and controlling the NK cell killing of cancer cells. Once the NK cells identify MICA or MICB emerging from cancerous cells, the faculty to quash cancer cells diminishes.
For its project with CanCure, CHA Biotech plans to review the therapeutic effect and level of effectiveness of the combined MIC-targeted antibodies and allogeneic NK cells. CHA Biotech stated, “CanCure’s anti-MIC antibody can reverse the immune suppression of tumor-shed MIC and enhance the tumor-killing ability of NK cells, allowing NK cells more powerful control of cancer cells.”
CHA Biotech and CanCure’s Agreement
Korea Biomedical Review reported that under the agreement signed by CHA Biotech and CanCure, the South Korean biotech firm will receive a material transfer of antibodies that focuses on MHC class I antigens from the latter. After the clinical plan is finalized, the former will check the therapeutic effects of the antibodies and NK cells in different cancer models.
Lee Jung Hyun, the chief executive officer of CHA Biotech, added, “To expand and strengthen CHA Biotech’s NK cell therapy pipelines, we are pursuing multiple combination strategies with immune checkpoint inhibitors and antibodies. We are planning on increasing the speed and success rate of clinical trials for our NK cell therapy through an open innovation approach with novel biopharmaceuticals and technologies.”
Photo by: CHA Biotech Website
